Complex Regional Pain Syndromes
Conditions
Keywords
Complex Regional Pain Syndromes, drug therapy, zoledronic acid
Brief summary
To evaluate the efficacy and the safety of using a single, intravenous 5mg dose of zoledronic acid in managing pain in Complex Regional Pain Syndrome patients.
Detailed description
Complex regional pain syndrome (CRPS) is a disorder of the extremities that is characterized by spontaneous unexplained disproportionate pain, hyperalgesia, swelling, limited range of motion, vasomotor instability, skin changes, and patchy bone demineralization.The incidence of CRPS was estimated to be 5.46 per 100,000 person years at risk in Olmsted County, Minnesota (US), with a prevalence of 20.57 per 100,000, while its incidence in the general population of the Netherlands was estimated to be much higher, at 26.2 per 100,000 person-years. The adverse effects were not serious and lasted just a few days. The beneficial effects of other bisphosphonates have been already documented in several placebo-controlled trials; however, there are no reports on the use of zoledronic acid to reduce pain in CRPS patients.
Interventions
DRUGZoledronic acid
One single dose of 5mg intravenous infusion of zoledronic acid (interventional group)
DRUGPlacebo
one single intravenous infusion of 100ml of saline.
Sponsors
Novartis
University of Sao Paulo General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients over 18 years of age of both genders, with continuing pain that is disproportionate to any inciting event, with cardinal features of CRPS. 2. Pain - after initial injury with signs and symptoms present at first visit 3. History of previous unsuccessful treatment for pain, with a minimum of two drug therapies, such as non steroidal anti-inflammatory drugs, steroids, antidepressants, central acting analgesics, calcitonin or sympathetic blocks, (not bisphosphonates) for at least six months. 4. Must report at least one symptom in three of the four following categories: 1. Sensory: Reports of hyperesthesia and/or allodynia 2. Vasomotor: Reports of temperature asymmetry and/or skin color changes and/or skin color asymmetry 3. Sudomotor/Edema: Reports of edema and/or sweating changes and/or sweating asymmetry 4. Motor/Trophic: Reports of decreased range of motion and/or motor dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, nail, skin). 5. Must display at least one sign\* at time of evaluation in two or more of the following categories: 1. Sensory: Evidence of hyperalgesia (to pinprick) and/or allodynia (to light touch and/or deep somatic pressure and/or joint movement) 2. Vasomotor: Evidence of temperature asymmetry and/or skin color changes and/or asymmetry 3. Sudomotor/Edema: Evidence of edema and/or sweating changes and/or sweating asymmetry 4. Motor/Trophic: Evidence of decreased range of motion and/or motor dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, nail, skin). 6. Skin temperature of the affected side equal or higher than on the non-affected side. 7. No other diagnosis better explains the signs and symptoms.
Exclusion criteria
1. Presence of systemic diseases including diabetes mellitus, hyperthyroidism, renal and liver dysfunction, peripheral vascular or cardiovascular diseases, uncontrolled hypertension, rheumatoid and hematopoietic diseases, neurological diseases not related to CRPS, overt alcohol addiction, positive pregnancy test and/or lactating women, hyperparathyroidism, and hypocalcaemia. 2. Creatinine clearance \<35mL/min, with serum creatinine measured before the dose of zoledronic acid. 3. Pre-existing hypocalcaemia and disturbance of mineral metabolism (e.g. hyperparathyroidism, thyroid surgery, parathyroid surgery, malabsorption syndromes, and excision of small intestine). 4. Hypersensitivity to zoledronic acid or any component drugs used in the trial. 5. Patients with asthma and aspirin-sensitivity 6. Pregnancy or unwillingness to use contraceptive methods during the trial 7. Patients who have previously used any kind of bisphosphonate, especially zoledronic acid. 8. Osteoporosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain measured on Visual Analog Scale | up to 12 months after treatment |
Secondary
| Measure | Time frame |
|---|---|
| Lower Limbs vertical force on Wii platform | Baseline, 3, 6 and 12 months |
| American Orthopaedic Foot and Ankle Scale (AOFAS) | Baseline, 3, 6 and 12 months after treatment |
| 36-Item Short Form Health Survey (SF-36) | Baseline, 3, 6 and 12 months after treatment |
Countries
Brazil
Contacts
Primary ContactPerola Grinberg Plapler, MD
Backup ContactMarta Imamura, MD
Outcome results
None listed